HC Wainwright Reaffirms “Buy” Rating for Arcturus Therapeutics (NASDAQ:ARCT)

HC Wainwright reissued their buy rating on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a research note released on Friday morning,Benzinga reports. They currently have a $63.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Arcturus Therapeutics’ FY2028 earnings at $13.21 EPS.

Other equities analysts also recently issued research reports about the company. Leerink Partnrs raised Arcturus Therapeutics to a “strong-buy” rating in a research report on Monday, August 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th. Finally, Leerink Partners assumed coverage on Arcturus Therapeutics in a research note on Monday, August 12th. They issued an “outperform” rating and a $70.00 price target for the company. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $71.40.

Arcturus Therapeutics Stock Up 4.7 %

Shares of NASDAQ:ARCT traded up $0.89 during midday trading on Friday, reaching $19.63. The company had a trading volume of 386,629 shares, compared to its average volume of 466,985. The business’s 50 day moving average price is $20.61 and its 200 day moving average price is $24.26. The stock has a market cap of $528.54 million, a PE ratio of -8.84 and a beta of 2.64. Arcturus Therapeutics has a 1-year low of $17.26 and a 1-year high of $45.00.

Insider Buying and Selling

In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total transaction of $249,120.00. Following the completion of the transaction, the chief operating officer now owns 435,334 shares of the company’s stock, valued at approximately $9,037,533.84. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 15.30% of the stock is owned by insiders.

Institutional Trading of Arcturus Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. purchased a new position in shares of Arcturus Therapeutics during the 1st quarter worth about $40,000. ProShare Advisors LLC bought a new position in shares of Arcturus Therapeutics during the 1st quarter worth approximately $205,000. State Board of Administration of Florida Retirement System increased its stake in Arcturus Therapeutics by 32.3% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 8,841 shares of the biotechnology company’s stock valued at $299,000 after purchasing an additional 2,160 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its stake in Arcturus Therapeutics by 10.5% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company’s stock valued at $152,000 after purchasing an additional 428 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in Arcturus Therapeutics by 5.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 17,004 shares of the biotechnology company’s stock valued at $575,000 after purchasing an additional 922 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.